Skip to content

Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01229540
Enrollment
Unknown
Registered
2010-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2010-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy., The Mechanism of Retinal Neovascularization of Diabetic

Brief summary

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.

Interventions

GENETICgenetic analyzer

Sponsors

Tianjin Medical University
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
45 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

* T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL). * DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography. * All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion criteria

* Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026